MiniMed appointed David Endicott and Linnea Burman to its Board of Directors on June 29, 2026, expanding the Board from nine to 11 members. The appointments strengthen the company's governance as it operates as an independent diabetes technology leader following its separation and IPO earlier this year. Endicott will serve as a member of the Board's Compensation and Talent Committee.

David Endicott is the Chief Executive Officer of Alcon, an eye care company, and has served on Alcon's board since 2019. He joined Alcon in July 2016 as Chief Operating Officer and became Chief Executive Officer in July 2018, leading the company's spin out and return to public markets. Previously, he was President of Hospira Infusion Systems, a Pfizer company, and spent over 25 years at Allergan in leadership roles across the United States, Europe, Asia, and Latin America. Endicott currently serves on the board of AdvaMed and previously served on the boards of Zeltiq, Inc. and Orexigen Therapeutics, Inc.

Linnea Burman was designated to the Board by Medtronic plc, which remains the majority shareholder following MiniMed's separation. She is currently Senior Vice President and President, Neurovascular at Medtronic. Burman has held various senior operating and strategic leadership roles during her more than 19 years at the company, including Vice President and General Manager positions in Enabling Technologies, Cranial and Spinal Technologies, and Pelvic Health and Gastric Therapies.

New Board Profiles

Que Dallara, Chief Executive Officer of MiniMed, highlighted the value of Endicott's experience in scaling global healthcare businesses and leading through public market separations. Endicott expressed his honor in joining the Board, citing MiniMed's track record in diabetes and its opportunity to simplify care globally. The company continues to build its position as a focused, independent diabetes technology leader.

MiniMed has commercially launched the MiniMed 780G system integrated with the Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor in Europe. The Instinct and Instinct Go sensors, made by Abbott, are being rolled out gradually across European markets starting this month. This expansion allows more people with diabetes to access advanced technology while maintaining proven clinical performance.

The MiniMed 780G system features Meal Detection technology designed to reduce post-meal blood glucose spikes when users occasionally forget to bolus or underestimate carbs. Paired with the 15-day Instinct sensor, which is described as the world's smallest, thinnest, and most discreet sensor, the system offers greater flexibility. A randomized crossover study published in Diabetes Technology & Therapeutics demonstrated that glycemic outcomes were virtually identical when using the MiniMed 780G system with either the Simplera Sync sensor or Instinct sensor.

Clinical and real-world evidence indicates the MiniMed 780G system can help people with type 1 diabetes achieve consistent glycemic control. Many users achieve 80% Time in Range (TIR) when using optimal settings, substantially exceeding ADA and international consensus guidelines of 70% TIR. A separate real-world study of 8,019 U.S. users demonstrated that the system delivered 91% overnight Time in Range.

For users managing diabetes with multiple daily injections (MDI), the MiniMed Go system integrates the Instinct Go sensor with the InPen smart insulin pen. This solution combines dose tracking with real-time CGM data to address therapy adherence gaps. It provides real-time alerts and actionable insights on a single mobile app when doses are missed or blood glucose spikes occur.

The integration of the Instinct sensor with MiniMed systems follows CE mark approval earlier this year. Professor Amir Tirosh of Sheba Medical Center and Tel-Aviv University noted that the integration allows more people to access advanced diabetes technology in a way that works for them while still benefiting from proven algorithms and clinical outcomes.

Key System Features